Literature DB >> 19762485

Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance.

Antonina V Kurtova1, Kumudha Balakrishnan, Rong Chen, Wei Ding, Susanne Schnabl, Maite P Quiroga, Mariela Sivina, William G Wierda, Zeev Estrov, Michael J Keating, Medhat Shehata, Ulrich Jäger, Varsha Gandhi, Neil E Kay, William Plunkett, Jan A Burger.   

Abstract

Marrow stromal cells (MSCs) provide important survival and drug resistance signals to chronic lymphocytic leukemia (CLL) cells, but current models to analyze CLL-MSC interactions are heterogeneous. Therefore, we tested different human and murine MSC lines and primary human MSCs for their ability to protect CLL cells from spontaneous and drug-induced apoptosis. Our results show that both human and murine MSCs are equally effective in protecting CLL cells from fludarabine-induced apoptosis. This protective effect was sustained over a wide range of CLL-MSC ratios (5:1 to 100:1), and the levels of protection were reproducible in 4 different laboratories. Human and murine MSCs also protected CLL cells from dexamethasone- and cyclophosphamide-induced apoptosis. This protection required cell-cell contact and was virtually absent when CLL cells were separated from the MSCs by micropore filters. Furthermore, MSCs maintained Mcl-1 and protected CLL cells from spontaneous and fludarabine-induced Mcl-1 and PARP cleavage. Collectively, these studies define common denominators for CLL cocultures with MSCs. They also provide a reliable, validated tool for future investigations into the mechanism of MSC-CLL cross talk and for drug testing in a more relevant fashion than the commonly used suspension cultures.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19762485      PMCID: PMC4081374          DOI: 10.1182/blood-2009-07-233718

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  64 in total

1.  Bone biopsy derived marrow stromal elements rescue chronic lymphocytic leukemia B-cells from spontaneous and drug induced cell death and facilitates an "angiogenic switch".

Authors:  Neil E Kay; Tait D Shanafelt; Ann K Strege; Yean K Lee; Nancy D Bone; Azra Raza
Journal:  Leuk Res       Date:  2007-01-22       Impact factor: 3.156

2.  Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.

Authors:  Constantine S Tam; Susan O'Brien; William Wierda; Hagop Kantarjian; Sijin Wen; Kim-Anh Do; Deborah A Thomas; Jorge Cortes; Susan Lerner; Michael J Keating
Journal:  Blood       Date:  2008-04-14       Impact factor: 22.113

Review 3.  Positive and negative selection events during B lymphopoiesis.

Authors:  F Melchers; A Rolink; U Grawunder; T H Winkler; H Karasuyama; P Ghia; J Andersson
Journal:  Curr Opin Immunol       Date:  1995-04       Impact factor: 7.486

4.  Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells.

Authors:  Meike Burger; Tanja Hartmann; Myriam Krome; Justyna Rawluk; Hirokazu Tamamura; Nobutaka Fujii; Thomas J Kipps; Jan A Burger
Journal:  Blood       Date:  2005-05-19       Impact factor: 22.113

5.  Differential regulation of primitive human hematopoietic cells in long-term cultures maintained on genetically engineered murine stromal cells.

Authors:  H J Sutherland; C J Eaves; P M Lansdorp; J D Thacker; D E Hogge
Journal:  Blood       Date:  1991-08-01       Impact factor: 22.113

6.  Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.

Authors:  Michael J Borowitz; Meenakshi Devidas; Stephen P Hunger; W Paul Bowman; Andrew J Carroll; William L Carroll; Stephen Linda; Paul L Martin; D Jeanette Pullen; David Viswanatha; Cheryl L Willman; Naomi Winick; Bruce M Camitta
Journal:  Blood       Date:  2008-04-03       Impact factor: 22.113

7.  Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1.

Authors:  Joseph T Opferman; Anthony Letai; Caroline Beard; Mia D Sorcinelli; Christy C Ong; Stanley J Korsmeyer
Journal:  Nature       Date:  2003-12-11       Impact factor: 49.962

8.  Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100.

Authors:  Bruno Nervi; Pablo Ramirez; Michael P Rettig; Geoffrey L Uy; Matthew S Holt; Julie K Ritchey; Julie L Prior; David Piwnica-Worms; Gary Bridger; Timothy J Ley; John F DiPersio
Journal:  Blood       Date:  2008-12-02       Impact factor: 22.113

9.  VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia.

Authors:  Yean K Lee; Nancy D Bone; Ann K Strege; Tait D Shanafelt; Diane F Jelinek; Neil E Kay
Journal:  Blood       Date:  2004-03-02       Impact factor: 22.113

10.  VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis.

Authors:  Steven Le Gouill; Klaus Podar; Martine Amiot; Teru Hideshima; Dharminder Chauhan; Kenji Ishitsuka; Shaji Kumar; Noopur Raje; Paul G Richardson; Jean-Luc Harousseau; Kenneth C Anderson
Journal:  Blood       Date:  2004-06-24       Impact factor: 22.113

View more
  144 in total

1.  Gene immunotherapy of chronic lymphocytic leukemia: a phase I study of intranodally injected adenovirus expressing a chimeric CD154 molecule.

Authors:  Januario E Castro; Johanna Melo-Cardenas; Mauricio Urquiza; Juan S Barajas-Gamboa; Ramin S Pakbaz; Thomas J Kipps
Journal:  Cancer Res       Date:  2012-04-13       Impact factor: 12.701

2.  BCL2 suppresses PARP1 function and nonapoptotic cell death.

Authors:  Chaitali Dutta; Tovah Day; Nadja Kopp; Diederik van Bodegom; Matthew S Davids; Jeremy Ryan; Liat Bird; Naveen Kommajosyula; Oliver Weigert; Akinori Yoda; Hua Fung; Jennifer R Brown; Geoffrey I Shapiro; Anthony Letai; David M Weinstock
Journal:  Cancer Res       Date:  2012-06-11       Impact factor: 12.701

Review 3.  The B-cell receptor signaling pathway as a therapeutic target in CLL.

Authors:  Jennifer A Woyach; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2012-06-19       Impact factor: 22.113

4.  Modeling the marrow stem cell niche in vitro: is proximity the key to reproduction?

Authors:  Sabine Ponader; Jan A Burger
Journal:  Haematologica       Date:  2010-09       Impact factor: 9.941

5.  Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia.

Authors:  Rosa Lapalombella; Qingxiang Sun; Katie Williams; Larissa Tangeman; Shruti Jha; Yiming Zhong; Virginia Goettl; Emilia Mahoney; Caroline Berglund; Sneha Gupta; Alicia Farmer; Rajeswaran Mani; Amy J Johnson; David Lucas; Xiaokui Mo; Dirk Daelemans; Vincent Sandanayaka; Sharon Shechter; Dilara McCauley; Sharon Shacham; Michael Kauffman; Yuh Min Chook; John C Byrd
Journal:  Blood       Date:  2012-10-03       Impact factor: 22.113

6.  Mesenchymal stem cells and endothelial progenitor cells decrease renal injury in experimental swine renal artery stenosis through different mechanisms.

Authors:  Xiang-Yang Zhu; Victor Urbieta-Caceres; James D Krier; Stephen C Textor; Amir Lerman; Lilach O Lerman
Journal:  Stem Cells       Date:  2013-01       Impact factor: 6.277

7.  CD84 regulates PD-1/PD-L1 expression and function in chronic lymphocytic leukemia.

Authors:  Hadas Lewinsky; Avital F Barak; Victoria Huber; Matthias P Kramer; Lihi Radomir; Lital Sever; Irit Orr; Vita Mirkin; Nili Dezorella; Mika Shapiro; Yosef Cohen; Lev Shvidel; Martina Seiffert; Yair Herishanu; Shirly Becker-Herman; Idit Shachar
Journal:  J Clin Invest       Date:  2018-11-05       Impact factor: 14.808

8.  RelB, together with RelA, sustains cell survival and confers proteasome inhibitor sensitivity of chronic lymphocytic leukemia cells from bone marrow.

Authors:  Jingjing Xu; Peng Zhou; Wenjuan Wang; Aining Sun; Feng Guo
Journal:  J Mol Med (Berl)       Date:  2013-09-17       Impact factor: 4.599

9.  Impact of oxygen concentration on growth of mesenchymal stromal cells from the marrow of patients with chronic lymphocytic leukemia.

Authors:  Jessie-F Fecteau; Davorka Messmer; Suping Zhang; Bing Cui; Liguang Chen; Thomas J Kipps
Journal:  Blood       Date:  2012-12-18       Impact factor: 22.113

10.  Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies.

Authors:  Elisa Ten Hacken; Rebecca Valentin; Fara Faye D Regis; Jing Sun; Shanye Yin; Lillian Werner; Jing Deng; Michaela Gruber; Jessica Wong; Mei Zheng; Amy L Gill; Michael Seiler; Peter Smith; Michael Thomas; Silvia Buonamici; Emanuela M Ghia; Ekaterina Kim; Laura Z Rassenti; Jan A Burger; Thomas J Kipps; Matthew L Meyerson; Pavan Bachireddy; Lili Wang; Robin Reed; Donna Neuberg; Ruben D Carrasco; Angela N Brooks; Anthony Letai; Matthew S Davids; Catherine J Wu
Journal:  JCI Insight       Date:  2018-10-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.